Halotherapy relieves chronic obstructive pulmonary disease by alleviating NLRP3 inflammasome-mediated pyroptosis

Chenyan Zhang1#, Weijie Zhu1#, Qinghai Meng1, Naqi Lian1, Jingzhen Wu1, Bowen Liu1, Hao Wang1, Xinyu Wang2, Shujun Gu2, Jingli Wen2, Xiaoling Shen3, Yu Li1, Xu Qi2,4

1School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China; 2Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; 3Nanjing Kuancheng Technology Co., Ltd., Nanjing, China; 4The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, China

Contributions: (I) Conception and design: All authors; (II) Administrative support: Y Li, X Qi; (III) Provision of study materials or patients: Y Li, X Qi; (IV) Collection and assembly of data: C Zhang, W Zhu; (V) Data analysis and interpretation: C Zhang, W Zhu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Yu Li. School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China. Email: liyu@njucm.edu.cn; Xu Qi. Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou 210046, China. Email: qixuly@163.com.
Rivista, Fonte: ATM
Link Rivista: Link

A review of halotherapy for chronic obstructive pulmonary disease

Halotherapy improves the prognosis of acute respiratory distress syndrome and alleviated pyroptosis related biomarkers

Halotherapy relieves chronic obstructive pulmonary disease by alleviating NLRP3 inflammasome-mediated pyroptosis